CPRIT awards seven grants, totaling $23 million

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS awarded seven grants through its academic research program. The grants, totaling $23 million, support the recruitment of seven cancer scientists to academic institutions in Texas, including two distinguished senior researchers.

The awarded grants include the recruitment of first-time, tenure-track faculty members:

Charles Lin, recruitment to Baylor College of Medicine from the Dana-Farber Cancer Institute – $2,000,000

Leng Han, recruitment to The University of Texas Health Science Center at Houston from MD Anderson Cancer Center – $2,000,000

Jan Erzberger, recruitment to The University of Texas Southwestern Medical Center from ETH Zurich (Eidgenossische Technische Hochschule) – $2,000,000

Kendra Frederick, recruitment to The University of Texas Southwestern Medical Center from the Whitehead Institute for Biomedical Research – $3,000,000

Peter Douglas, recruitment to The University of Texas Southwestern Medical Center from the University of California, Berkeley – $2,000,000

The awards also include the recruitment of established investigators:

Frank McKeon, recruitment to the University of Houston from the Genome Institute of Singapore – $6,000,000

Yang-Xin Fu, recruitment to The University of Texas Southwestern Medical Center from the University of Chicago – $6,000,000

Additionally, members of the CPRIT Oversight Committee elected Pete Geren as presiding officer and Will Montgomery as vice presiding officer. Geren, who was vice presiding officer, replaces William Rice, whose term as presiding officer expired. Amy Mitchell was re-elected as secretary of the committee. Geren, Montgomery and Mitchell have been on the commitee since 2013.

Geren is the president of the Sid W. Richardson Foundation. From 2001 to 2009, he served in the U.S. Department of Defense as special assistant to the secretary of defense, acting secretary of the Air Force, undersecretary of the Army and secretary of the Army. He also served four terms in the House of Representatives and was formerly an assistant to Sen. Lloyd Bentsen.

Montgomery is a partner at the law firm Jackson Walker LLP, where his practice focuses on commercial litigation and arbitration.

Mitchell, a cancer survivor, works as an attorney in the real estate practice group of Fulbright & Jaworski’s Austin office. She has been included in Real Estate Law’s “The Best Lawyers in America” listing for the past six years and was named “Texas Top Rated Lawyer” by LexisNexis Martindale-Hubbell.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login